Yazar "Artaç, Mehmet" seçeneğine göre listele
Listeleniyor 1 - 11 / 11
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe CD19 Molekül Eksikliği: Bir Köy Taraması(Kare Publishing, 2009) Reisli, İsmail; Artaç, Hasibe; Pekcan, Sevgi; Kara, Reyhan; Yümlü, Kadir; Karagöl, Cüneyt; Çimen, Ömer; Şen, Metin; Artaç, MehmetAim: We identified a new CD19 deficient case who was a relative of the first CD19 deficient patient and lived in the same village. These cases suggested that other patients with CD19 deficiency or carriers could be found in this village. The aim of this study was to assess the warning signs of primary immunodeficiency and the CD19 molecule deficiency in this population. Material and Method: The relatives of CD19 deficient patients and controls were examined for the warning signs of primary immunode- ficiency using a questionnaire form. Blood samples were taken from these subjects. CD19 and CD21 expressions (median fluorescent intensity, MFI) were analyzed by flowcytometry in these samples. Results: A total of 208 subjects (59 families, 126 females, 82 males) including 129 children 9.5±3.7 years and 79 adults (37±13 years) were evaluated. A new case with CD19 deficiency was not detected. There was at least one warning sign for immunodeficiency in 67 subjects (57 children and 10 adults). CD19 median expression value was lower than 60 MFI value in 20 subjects, which was known as in the carriers who were detected to have heterozygous mutation. Conclusions: Our findings suggested that CD19 median expression might be a diagnostic tool for the subjects who have CD19 heterozygous mutations. Mutation analyses are planned for the confirmation of CD19 heterozygous mutation in these subjects who have low CD19 median expression.Öğe Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer(AKAD DOKTORLAR YAYINEVI, 2013) Karaca, Halit; Geredeli, Çağlayan; Kaplan, M. Ali; Demirci, Umut; Alıcı, Süleyman; Artaç, Mehmet; Işıkdoğan, AbdurrahmanErlotinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, with single-agent antitumor activity which improves symptom control and quality of life compared with placebo in non-small-cell-lung cancer (NSCLC) patients. We aimed to determine the efficacy and safety of the second, third or fourth-line erlotinib in advanced NSCLC patients in Turkish population. Eighty patients (33 males and 47 females) were retrospectively evaluated. All patients had received a platinum-based regimen as the first-line metastatic therapy. Most of the patients (62.5%) had received erlotinib as the second-line treatment. None of the patients had EGFR mutation studied. One patient achieved a complete response, 10 patients partial response and 21 stable diseases. The overall response rate was 14% and disease control rate was 40%. The median progression-free survival (PFS) and overall survival (OS) were 12 months and 18 months, respectively. Although, there was no survival difference between male and female patients, the median PFS of females was significantly better than male patients (p=0.03). There was no significant difference in disease control rate in terms of age, smoking status, erlotinib line, performance status (PS), stage and skin rash. The most common adverse events were skin rash (56%), diarrhea (9%) and anorexia (8%). Sixteen patients (20%) developed grade 3 toxicities. Grade 4 toxicity or treatment related interstitial lung disease were not observed. Erlotinib showed an acceptable response rate, survival time and toxicity after disease progression with chemotherapy. It's an alternative therapy as a second or third-line therapy in patients with NSCLC. Prospective studies are needed to evaluate the efficiency of the treatment in Turkish population.Öğe Gene Methylation of SFRP2, P16, DAPKI, HIC1, and MGMT and KRAS Mutations in Sporadic Colorectal Cancer(Elsevier Science Inc, 2010) Pehlivan, Sacide; Artaç, Mehmet; Sever, Tuğçe; Bozcuk, Hakan; Kılınçarslan, Can; Pehlivan, MustafaThe aim of this study was to investigate the methylation of the SFRP2, P16, DAPK1, HIC1, and MGMT genes, as well as the mutation of amino acid codons 12 and 13 of the KRAS gene in normal and tumor tissue DNA of patients diagnosed with sporadic colorectal cancer (SCRC). The methylation of gene regions and the KRAS mutations of normal (N) and tumor tissue (T) DNA obtained from 17 patients diagnosed with SCRC and 20 healthy controls were investigated using the polymerase chain reaction and reverse-hybridization methods. There was an Asp mutation in four patients, an Asp and Ser mutations in one patient in codon 12 of the KRAS gene, and an Asp mutation in codon 13 in eight patients. Overall promoter methylation (OPM) in the SFRP2 gene was observed in one N and four T, whereas partial promoter methylation (PPM) was observed in two N and five T. OPM in the P16 gene was present in one T. In the DAPK1 gene, OPM existed in seven T and five N, while PPM was present in two N. In the HIC1 gene, OPM was demonstrated in three T, while PPM was noted in two N; however, no methylation existed in N. In the MGMT gene, OPM occurred in five T and two N, and PPM was present in one T. KRAS mutations in Turkish patients with SCRC are similar to those of other population groups. Methylations in the genes, which underwent methylation analysis, were higher in Tin comparison with N, and it has been suggested that significant results would be obtained by making a study with a larger population.Öğe THE IMPACT OF LEPTIN AND ESTRADIOL LEVELS ON CLINICAL OUTCOMES IN METASTATIC BREAST CANCER (MBC) PATIENTS TREATED WITH AROMATASE INHIBITORS (AIS)(OXFORD UNIV PRESS, 2008) Artaç, Mehmet; Samur, Mustafa; Kıyıcı, Aysel; Afacan, Berna; Özdoğan, Mustafa; Bozcuk, Hakan[Abstract not Available]Öğe The impact of waist-to-hip ratio (WHR) on survival in metastatic breast cancer patients treated with aromatase inhibitors (AIs)(AMER SOC CLINICAL ONCOLOGY, 2007) Artaç, Mehmet; Samur, Mustafa; Bozcuk, Hakan; Afacan, Berna; Özdoğan, Mustafa[Abstract not Available]Öğe The impact of waist-to-hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors(Churchill Livingstone, 2008) Artaç, Mehmet; Bozcuk, Hakan; Afacan, Berna; Özdoğan, Mustafa; Samur, MustafaWe aimed to identify whether abdominal fat distribution could affect the outcome in metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs) or not. A total of 42 MBC patients treated with first line hormonal therapy were enrolled in this study. Factors associated with overall survival in the univariate analysis were age, c-erb-B2 expression intensity (+++ versus others by immunohistochemistry), and WHR, whereas only WHR retained significance in the multivariate analysis. Median overall survival figures were 472 days versus unreached for patients with a WHR of <0.92 and ?0.92 (Log rank statistic = 9.76, P = 0.002). Similarly, the corresponding progression free survival figures for patients with a WHR of <0.92 and ?0.92 were 423 versus 1004 days (Log rank statistic = 6.37, P = 0.012). This study suggests that WHR may serve as a potential predictive marker in MBC patients treated with AIs. © 2008 Elsevier Ltd. All rights reserved.Öğe Kolon kanserli hastalarda T lenfosit alt gruplarında vasküler endotelyal büyüme faktörü reseptörü ile epidermal büyüme faktörü reseptör ekspresyonlarının değerlendirilmesi(Selçuk Üniversitesi, Sağlık Bilimleri Enstitüsü, 2023) Artaç, Mehmet; Emiroğlu, MelikeGiriş: Kolon kanseri için önemli yolaklar olan VEGFR ve EGFR' nin lenfositler üzerindeki ekspresyonu ve bunun diğer prognostik faktörlerle ilişkisi bilinmemektedir. Bu çalışma, kolon kanserli hastalarda dolaşan T hücre alt grupları arasındaki VEGFR ve EGFR ekspresyon farklılığını ortaya koymak ve bunların prognostik faktörlerle ilişkisini ortaya çıkarmak için yapılmıştır. Gereç ve Yöntem: Prospektif olarak seçilen çalışma grubu histolojik olarak doğrulanmış kolon kanseri olan 52 hasta ve kontrol grubu olarak herhangi bir kanser öyküsü olmayan 30 kişiden oluşmuştur. Hastalardan tanı konulduktan sonra kemoterapi ve radyoterapiye başlamadan önce periferik kan örnekleri toplanmıştır. Aktif enfeksiyonu veya otoimmün bozukluğu olan ve çalışmaya kaydolmadan önceki son dört hafta içinde steroid ve antibiyotik tedavisi gören hastalar çalışma grubundan çıkarılmıştır. Dolaşımdaki T hücre alt kümelerindeki (Th1, Th2, Th17, STL) VEGFR2 ve EGFR ekspresyonları akış sitometrisi ile analiz edilmiştir. Hastaların klinik bilgilerine hasta dosyalarından ulaşılmıştır. Bulgular: Çalışmaya dahil edilen kolon kanserli olguların 30'u (%57,7) erkek, 22'si (%42,3) kadın idi. Kontrol grubunun ise 16'sı (%53,3) erkek, 14'ü (%46,7) kadın idi. Hasta ve kontrol grupları arasında cinsiyet ve yaş ortalaması açısından anlamlı fark yoktu (p > 0,05). Kolon kanserli hastaların nötrofil/lenfosit oranı (NLR) ve CEA seviyeleri normal sınırlara göre artmıştı. İleri evre hastalarda Th1 hücreleri kontrole göre daha yüksek ve CD4+ Tfh'leri ise daha düşüktü (p = 0,01). CD8+ Tfh'lerinde ileri evre hastalarda erken evre hastalara göre artış saptandı (p = 0,02). Kolon kanserli hastaların CD3+ T hücre ve CD4+ Th hücrelerinde EGFR yüzde oranı kontrole göre düşüktü (sırasıyla, p = 0,001, p = 0,03). Lenfosit, CD3+ T hücre, CD4+ Th, Th1, Th2, Th17 ve CD4+ Tfh hücrelerinin EGFR yüzey ekspresyonunda ise artış saptandı. Kolon kanserli hastalarda CD3+ T hücre ve CD4+ Tfh'lerin VEGFR yüzde oranı ile CD4+ Tph'lerin VEGFR ekspresyonu kontrol grubuna göre düşüktü (sırasıyla, p = 0,047, p = 0,04, p = 0,049). Th1, Th2, CD4+ Tfh, CD8+ STL ve CD8+ Tfh'lerinin VEGFR ekspresyonları kontrole göre artmıştı. Tartışma: Bu çalışmada literatürde ilk defa olarak, kolon kanserinde periferal T lenfosit alt gruplarında lenfosit yüzeyindeki VEGFR ve EGFR yüzey ekspresyonlarının önemi ortaya kondu. Lenfosit yüzeyindeki bu reseptörlerin kolon kanseri ile ilişkili prognostik biyobelirteçlerle ilişkisi değerlendirilerilerek literatüre önemli bir katkı sağlanmıştır. Bu konuda daha ileri çalışmalara ihtiyaç vardır.Öğe Kolorektal Kanserli Hastalarda Sitokrom P450 (CYP2C9 ve CYP2C19) Genetik Polimorfizm Sıklığı(2009) Büyükdoğan, Murat; Boruban, M. Cem; Artaç, Mehmet; Demirel, SennurÖzellikle gelişmiş ülkelerin önemli sağlık sorunlarından biri olan kolorektal kanserler, genetik ve çevresel faktörlerin katkılarıyla gelişen multifaktöriyel bir hastalıktır. Bu vaka kontrol çalışmasında kolorektal karsinoma ile CYP2C2 alt gurubunun bir üyesi olan endojen ve eksojen maddelerin karsinojenlerin ve ilaçların metabolizmasında önemli rol alan CYP2C9 ve CYP2C19 gen polimorfizmini ve aynı zamanda sigara, alkol, ailede kanser hikayesi, asbestoz maruziyeti gibi risk faktörlerini araştırdık. Çalışmaya ailesinde kanser hikayesi olmayan 85 sağlıklı gönüllü ile Meram Tıp Fakültesi Tıbbi Onkoloji ve Genel Cerrahi kliniklerine başvuran klinik ve histopatolojik olarak çoğunluğu adenokarsinom olan kolorektal kanserli 85 hasta alındı. CYP2C9 ve CYP2C19 genlerinin heterozigot ve mutant genotiplerini belirlemek için CYP2C9*2, CYP2C9*3 ve CYP2C19*2, CYP2C19*3 mutasyon saptama kitleri Light Cycler Real Time Polymerase Chain Reaction ile kullanıldı. Sonuçlar vaka ve kontrol guruplarında istatistiksel olarak karşılaştırıldı ve hesaplanan odds oranları kullanıldı. Kolorektal karsinomdaki risk faktörleri ve CYP2C9*2, CYP2C9*3 ve CYP2C19*2, CYP2C19*3 genlerinin polimorfik genotip sıklıklarının araştırıldığı bu vaka kontrol çalışmasında; kolorektal kanserli hastalar ve kontrol gurubu arasında anlamlı fark saptanamadı. (p > 0.05). Kolorektal kanserli hastalarda beyaz toprağa maruz kalanların oranı anlamlı oranda (p < 0.05) yüksek bulundu ve beyaz toprağın kolorektal kanser için bir risk faktörü olabileceği düşünüldü.Öğe Leptin and breast cancer: an overview(HUMANA PRESS INC, 2012) Artaç, Mehmet; Altundağ, KadriLeptin is a well-known mediator of obesity. Leptin and its receptor are overexpressed in breast cancer, especially in high-grade tumors. It has an association with progression and poor survival of breast cancer. Leptin can regulate endothelial cell proliferation and promote angiogenesis. There are several other factors such as insulin and HER2 may be involved in the relationship between leptin and breast cancer. Leptin system has emerged as a new and promising therapeutic target for breast cancer. This review article summarizes the current knowledge about the relation of leptin and breast cancer.Öğe The predictors of information needs and different views of patients and relatives on disclosure and treatment participation: A multicentric survey study(AMER SOC CLINICAL ONCOLOGY, 2009) Özdoğan, Mustafa; Bozcuk, Hakan; Er, O.; Abalı, Hüseyin; Coşkun, Hasan Şenol; Zengin, N; Artaç, Mehmet; Savaş, Burhan[Abstract not Available]Öğe The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens(SPRINGER, 2010) Artaç, Mehmet; Bozcuk, Hakan; Pehlivan, Sacide; Akcan, Songül; Pehlivan, Mustafa; Sever, Tuğçe; Özdoğan, MustafaPrevious studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR-RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.
